According to new research from InterStudy Publications, a division of Decision Resources, HMO Medicare enrollment in the six largest states (California, Texas, New York, Florida, Illinois, and Pennsylvania) increased by 16.4% between 2003 and 2004, while total HMO enrollment in these states declined by about 4% during the same time period. This research is based on analysis from InterStudy's newly released Fall 2004 HMO County Surveyor database, a leading source of standardized demographic and HMO industry information at the county level.

"The number of plans managing Medicare and Medicaid patients has risen, even as the total number of HMOs has decreased," said Lance Wolkenbrod, database specialist for InterStudy Publications. "This trend reflects federal and local governments' desire to control health care costs by having HMOs manage patient care."

About HMO County Surveyor

The HMO County Surveyor database is the first product to provide nationwide HMO enrollment data at the county level. The database is used by leading firms to analyze county-level HMO market share by total HMO, Medicare, and Medicaid enrollment. Data is available for purchase by individual county or state, or for the entire nation.

About InterStudy Publications

InterStudy Publications, a division of Decision Resources, offers data, directories, and analyses of the ever-evolving managed care industry. InterStudy tracks changes and trends in HMO and PPO services, enrollment, and profitability. Visit InterStudy Publications at

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Frank Sama    InterStudy Publications    781-296-2553 

SOURCE: InterStudy Publications

CONTACT: Frank Sama of InterStudy Publications, +1-781-296-2553,

Eli Lilly's Ruboxistaurin Poised to Transform the Diabetic Neuropathy Drug Market

View Now